The clinical efficacy of all-port robotic versus thoracoscopic lobectomy in stageⅠA non-small cell lung cancer: A retrospective cohort study
- VernacularTitle:全孔机器人与胸腔镜在ⅠA期非小细胞肺癌肺叶切除术中疗效比较的回顾性队列研究
- Author:
Lingqi YAO
1
;
Xiaoyan CHANG
1
;
Zhiping SHEN
1
;
Kaiyu WANG
1
;
Yi LI
1
;
Hao XU
1
;
Linyou ZHANG
1
Author Information
1. Department of Thoracic Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, P. R. China
- Publication Type:Journal Article
- Keywords:
StageⅠA non-small cell lung cancer;
robot-assisted thoracic surgery;
video-assisted thoracoscopic surgery;
lobectomy;
lymph node dissection
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2023;30(10):1390-1395
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the perioperative efficacy and safety of all-port robotic lobectomy versus thoracoscopic lobectomy in stageⅠA non-small cell lung cancer. Methods The clinical data of patients with stageⅠA non-small cell lung cancer who underwent lobectomy with lymph node dissection performed by the same operator in our center from June 2019 to June 2022 were retrospectively analyzed. The patients were divided into a robotic group and a thoracoscopic group according to different procedures. We compared the relevant indexes such as operation time, intraoperative bleeding, number of lymph node dissection stations, number of lymph node dissection, postoperative tube time, postoperative hospitalization time, closed chest drainage volume, postoperative pain, postoperative complications and hospitalization cost between the two groups. Results There were 83 patients in the robotic group, including 34 males and 49 females with a median age of 60.0 (53.0, 67.0) years, and 94 patients in the thoracoscopic group, including 36 males and 58 females with a median age of 60.5 (54.0, 65.3) years. There was no conversion to thoractomy or death in postoperative 90 days in both groups. No statistical difference was seen in the operation time, total postoperative drainage volume and postoperative complication rates between the two groups (P>0.05). Patients in the robotic group had less intraoperative bleeding (P<0.001), more lymph node dissection stations (P=0.002) and numbers (P=0.005), less postoperative pain (P=0.002), and shorter postoperative time with tubes (P=0.031) and hospital stay (P<0.001). However, the surgery was more expensive in the robotic group (P<0.001). Conclusion All-port robotic surgery is safe and effective for patients with early-stage non-small cell lung cancer with less intraoperative bleeding, more lymph node dissection, less postoperative pain, and shorter hospital stay compared with the thoracoscopic surgery.
